Marvel Biosciences Corp Cash Flow Conversion Efficiency
Marvel Biosciences Corp cash flow conversion efficiency. Based on the latest financial reports, Marvel Biosciences Corp (MRVL) has a cash flow conversion efficiency ratio of 0.049x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-178.46K ≈ $-129.09K USD) by net assets (CA$-3.65 Million ≈ $-2.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Marvel Biosciences Corp (2020–2025)
Cash flow conversion efficiency of Marvel Biosciences Corp from 2020 to 2025. This chart illustrates how Marvel Biosciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Marvel Biosciences Corp for real-time trading data and today's change.
Marvel Biosciences Corp Cash Flow Conversion Ratio Explained
Marvel Biosciences Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Marvel Biosciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marvel Biosciences Corp ranked by their cash flow conversion efficiency. Also see Marvel Biosciences Corp (MRVL) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
-0.522x |
|
Throgmorton Trust Plc
LSE:THRG
|
0.018x |
|
VITAL BATTERY METALS INC
F:C0O
|
N/A |
|
Gix Internet Ltd
TA:GIX
|
N/A |
|
Schroder Japan Growth Fund
LSE:SJG
|
0.001x |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
-0.002x |
|
Quantum Genomics SA
PA:ALQGC
|
3.110x |
|
SIV Capital Ltd
AU:SIV
|
0.020x |
Annual Cash Flow Conversion Efficiency for Marvel Biosciences Corp (2020–2025)
The table below shows the annual cash flow conversion efficiency of Marvel Biosciences Corp from 2020 to 2025. Review financial flexibility index of Marvel Biosciences Corp to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | CA$-4.01 Million ≈ $-2.90 Million |
CA$-1.15 Million ≈ $-832.13K |
0.287x | -31.21% |
| 2024-07-31 | CA$-2.83 Million ≈ $-2.04 Million |
CA$-1.18 Million ≈ $-853.23K |
0.417x | -46.11% |
| 2023-07-31 | CA$-1.72 Million ≈ $-1.24 Million |
CA$-1.33 Million ≈ $-963.72K |
0.775x | +106.90% |
| 2022-07-31 | CA$195.54K ≈ $141.45K |
CA$-2.19 Million ≈ $-1.59 Million |
-11.220x | -1828.46% |
| 2021-07-31 | CA$2.36 Million ≈ $1.70 Million |
CA$-1.37 Million ≈ $-991.45K |
-0.582x | +87.16% |
| 2020-07-31 | CA$118.80K ≈ $85.94K |
CA$-538.53K ≈ $-389.57K |
-4.533x | -- |
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more